H. Lundbeck AS (Lundbeck), a subsidiary of The Lundbeck Foundation, develops and markets drugs for the treatment of psychiatric and neurological disorders. It undertakes research and development, production, marketing, and sale of pharmaceuticals worldwide. The company's products target CNS disorders such as depression and anxiety, schizophrenia, insomnia, Huntington's, migraine, epilepsy, Alzheimer's and Parkinson's diseases, and other CNS disorders.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Lundbeck’s R&D projects focus on unmet medical needs of brain diseases such as depression and anxiety, psychosis, Alzheimer’s disease, Parkinson’s disease, epilepsy, stroke, alcohol dependence, and Lennox-Gastaut syndrome. The company has various products in the pipeline targeting other CNS disorders such as migraine, episodic cluster headache, Alzheimer's disease, neurohormonal dysfunctions, synucleinopathies, PTSD, Parkinson's disease, tauopathies, neurology, and bipolar I disorder. In hormonal or neuropeptide signaling, the company is evaluating Eptinezumab (anti-CGRP mAb) in Phase III stage for cluster headaches. It is evaluating Lu AG09222 (anti-PACAP mAb) in Phase II trial for migraine prevention. In the field of circuitry or neuronal biology, the company is evaluating Brexpiprazole in Phase III trial for PTSD. It is conducting a Phase II trial of Lu AF28996 (D1-D2 agonist) for the treatment of Parkinson’s Disease. The company entered into various collaborations to develop a strong global network in preclinical and clinical neuroscience research. It has various partnerships including 23andMe Inc, The Milken Institute, and RADAR-CNS. In FY2023, Lundbeck spent DKK3,457 million on its R&D, which as a percentage of revenue stood at 17.3%. It has research centers in the US and Denmark.